Roche adds manufacturing facility at Nutley campus
US facility will produce dosage forms of highly potent compounds for clinical trials
Swiss pharmaceutical firm Roche has opened a new 17,000ft2 (1,580m2) clinical supply manufacturing facility on its campus in Nutley, NJ, US.
The Roche Centre of Excellence will produce dosage forms of highly potent compounds for preclinical safety studies, and Phase I and II clinical studies.
‘This is a vitally important milestone for the Nutley site as well as pharmaceutical research and early development at Roche,’ said Waseem Malick, vice president of Pharmaceutical & Analytical R&D at Roche.
It has taken about a year to construct the facility, which will produce tablets, capsules, powders, suspensions and solutions. Scientists and engineers will manufacture clinical supplies of highly active compounds under current Good Manufacturing Practices (cGMP) for Roche trials worldwide.
The facility also contains warehouses for components, excipients (inactive ingredients) and active pharmaceutical ingredients (APIs), mechanical rooms and multipurpose isolation suites for manufacturing.